Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Beebe
The HSP90 Inhibitor Ganetespib Synergizes With the MET Kinase Inhibitor Crizotinib in Both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models
Cancer Research
Cancer Research
Oncology
Adenomatous Polyposis Coli Regulates Drosophila Intestinal Stem Cell Proliferation
Development (Cambridge)
Developmental Biology
Molecular Biology
Related publications
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer Research
Oncology
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
An Orally Bioavailable C-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Anti-Cancer Agents in Medicinal Chemistry
Cancer Research
Molecular Medicine
Pharmacology
Development of Crizotinib, a Rationally Designed Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor
OncoTargets and Therapy
Oncology
Pharmacology
Met Tyrosine Kinase Inhibitor, PF-2341066, Suppresses Growth and Invasion of Nasopharyngeal Carcinoma
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Response to Crizotinib in a Patient With MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib
European Urology
Urology
